Sign In
Buy MTSR
$70.50
+0 (+0%)
At Close: Feb 12, 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of M
IP Group: Metsera deal highlights hidden value, say analysts
07:33am, Monday, 13'th Oct 2025
Sometimes value can be hidden in plain sight. Berenberg thinks that is the case with IP Group PLC (LSE:IPO), the London-listed investor in university spin-outs, where it sees a “significant" oppor
IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal
05:35am, Monday, 13'th Oct 2025
Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 bil
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
03:39pm, Tuesday, 30'th Sep 2025
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
11:02am, Tuesday, 30'th Sep 2025
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Metsera's obesity drug shows promising weight loss in mid-stage trials
04:11pm, Monday, 29'th Sep 2025
Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies.
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatm
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
07:56pm, Tuesday, 23'rd Sep 2025
Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Metsera, Inc. (NASDAQ: MTSR)
05:30pm, Tuesday, 23'rd Sep 2025
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
10:47am, Tuesday, 23'rd Sep 2025
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly tow
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
02:50pm, Monday, 22'nd Sep 2025
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo
BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity
02:01pm, Monday, 22'nd Sep 2025
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ODP and MTSR on Behalf of Shareholders
11:25am, Monday, 22'nd Sep 2025
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
11:08am, Monday, 22'nd Sep 2025
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
